What is Progentec Diagnostics?
Progentec Diagnostics, Inc. operates at the forefront of precision medicine, specializing in proactive care solutions for autoimmune disorders. The company integrates advanced proteomics with digital health technologies to provide clinicians and patients with actionable insights. Its flagship aiSLE DX Family of Tests represents a significant advancement in the field, enabling the prediction of disease flares and the continuous monitoring of disease activity. Beyond diagnostics, the company fosters a comprehensive patient-centric ecosystem through its LupusCorner platform, which provides essential health management resources and community support. By combining proprietary blood biomarkers with remote digital monitoring, Progentec is effectively bridging the gap between clinical research and daily patient care, establishing a robust framework for long-term disease management.
How much funding has Progentec Diagnostics raised?
Progentec Diagnostics has raised a total of $5.2M across 2 funding rounds:
Series A
$5M
Debt
$172K
Series A (2020): $5M with participation from Burns & Stowers Investments LLC, OCA Ventures, Oklahoma Medical Research Foundation, Mayo Clinic, Plains Venture Partners, Oklahoma Seed Capital Fund, NMC Health, Stanford University, and Oklahoma Angel Capital Fund II
Debt (2021): $172K led by PPP
Key Investors in Progentec Diagnostics
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research. The institution is recognized for its multidisciplinary approach to patient care, bringing together specialists from various medical fields to address complex health conditions.
OCA Ventures
OCA Ventures is dedicated to assisting entrepreneurs in the development of successful companies by providing support and resources to help startups thrive. Their focus is on fostering innovation and growth among emerging businesses.
Stanford University
Stanford University is one of the world's leading research universities, known for its entrepreneurial character and interdisciplinary approach to problem-solving. The institution maintains a strong legacy of contributing to medical advancement and healthcare innovation.
What's next for Progentec Diagnostics?
With the recent capital injection, Progentec Diagnostics is poised to enter a new phase of operational scaling and technological refinement. The company is expected to prioritize the expansion of its aiSLE DX diagnostic suite, potentially targeting broader clinical applications and international market penetration. Furthermore, the integration of remote monitoring capabilities suggests a strategic focus on enhancing the LupusCorner platform to provide more personalized, data-driven health interventions. As the company continues to navigate the complexities of the autoimmune diagnostics market, its focus will likely remain on validating its biomarker technology through rigorous clinical research and fostering strategic partnerships with major healthcare institutions to standardize its diagnostic protocols globally.
See full Progentec Diagnostics company page
